Skip to end of metadata
-
Created by Former user, last modified by Former user on Apr 30, 2021
Go to start of metadata
You are viewing an old version of this page. View the current version.
Compare with Current
View Page History
« Previous
Version 41
Next »
Project Scope The increasing interest in including results based on Real World Data as part of regulated clinical trial submissions and similar research initiatives is testing how current regulatory and good practice requirements can incorporate these results into submissions. Whilst specific projects have successfully addressed these issues, Real World Evidence guidelines or points for consideration are not yet formalised. PHUSE members are involved in the management and analysis of these data, and best practices for dealing with Real World Evidence data that would assist members in this space. The project has three goals: Focus on Real World Evidence issues. Develop a White Paper presentation focused on establishing the range of areas that need to be considered/impact on the use of Real World Evidence in support of regulated clinical trial submissions. This would be focused on identifying issues such as data sources, Real World Evidence technologies, data privacy and related issues, standards etc. impacting on Real World Evidence use. (e.g. see PHUSE SDE London May 2019 presentations). Identify and prioritise future Real World Evidence projects/sub-projects.
|
|
---|
New Project for Phase II has been approved and the team have drafted an outline of the White Paper. Currently assigning project members to sections of the paper to curate. |
Objectives & Deliverables | Timelines |
---|
White Paper which establishes a range of areas that need to be considered/impact the use of Real World Evidence. | Draft: July 2021 |
Project Members | Organisation |
---|
Adam Reich | IQVIA |
Andy Steen | EDJ Analytics |
Anil Sekhari | Sekharico |
Aldir Medeiros Filho | Industry |
Bhanu Kannan | FDA |
Charan Kumar | Ephicacy |
Claudi Jimenez | Syneos Health |
Corey Young | EDJ Analytics |
Devaki Thavarajah | Industry |
Diego Saldana | Roche |
Elizabeth Merrall | S-cubed |
Hao Chen | Pfizer |
Jeff Abolafia | Pinnacle 21 |
Jingwen Zhang | Industry |
Kiichiro Toyoizumi | Shionogi |
Lisa Kang | PharmaEssentia |
Lisa Lin | FDA |
Marion Bonnet | Ipsen |
Marko Zivkovic | Genesis |
Michael Martinec | Roche |
Project Members | Organisation |
---|
Nicole Thorne | Janssen Research & Development |
Nurcan Coskun | Industry |
Oluseun Shittu | GlaxoSmithKline |
Paul Murray | SAS |
Pranab Mitra | Merck |
Rachel Bowman | Loxley Analytics |
Rosa Bianca Gallo | The Hyve |
Scott Bahlavooni | Nektar |
Siddharth Arthi | Zifo RnD Solutions |
Susan Eaton | Biogen |
Susan Olson | EDJ Analytics |
Susheel Arkala | MMS |
Shaojun Song | Yitu Technology |
Trisha Simpson | UCB |
Yixun Wu | Syneos Health |
Ingeborg Holt | IBM |
Sadchla Mascary | Pfizer |
Stella Munuo | AstraZeneca |
Swapna Kaveti | Industry |